There is a trust crisis today. Government is trusted a great deal by 16% of the populace, business by 17%, and the media by 17%. As dismal as those numbers are, should we at least find some solace in the fact that the 2013 numbers are all higher than 2012?

These figures come from Edelman's Trust Barometer for 2013, based on 31,000 respondents from around the world. A Forbes headline emphasized that 82% of people do not trust their boss to tell the truth.

Pretty much all businesses today get hammered by public mistrust, but in an editorial in JAMA, the authors underscore that "lack of trust in the pharmaceutical industry threatens the future of biomedical research." The comments are from Howard Bauchner, MD, and Phil B. Fontanarosa, MD, MBA—editor-in-chief and executive editor of JAMA, respectively—who certainly are familiar with the complicated issues related to industry-supported and -analyzed studies.

They cite reports of: manipulation and misrepresentation of data; important discrepancies between new drug applications and the published pivotal trial data; and substantial fines for unethical and illegal marketing practices.

As a result, recent data suggest that clinicians devalue the credibility of industry-funded trials, even when they are well-designed and well-executed.

Then there are those rare adverse events that can pummel a company's reputation in today's risk-averse society. Add in the fact that 2013 will see more than 40 brand-name products losing patent protection (with an estimated value of $35 billion in annual sales) and it's easy to imagine that biomedical research could be affected.

Restoring Confidence

Drs. Bauchner and Fontanarosa offer several suggestions to "help restore credibility and trust" in pharma-sponsored research. They suggest:

• Data analysis should be performed by academic investigators not employed by the company funding the research.
• Manuscripts should be written by the academic investigators, especially with respect to initial drafts, which establish the frame and tone of papers presenting study results.
• Clinical trial data could be made publicly available to qualified investigators for analyses.
• Pharmaceutical companies could voluntarily limit direct-to-consumer advertising until post-marketing studies are completed.

Given that three of these suggestions are already being implemented by some pharmaceutical companies, the editorial authors think there could be a reversal in the erosion of trust seen in the last decade or so.

Steven Nissen, MD, chairman of the department of cardiovascular medicine at the Cleveland Clinic, told CardioSource WorldNews: "I strongly agree with the JAMA editors. The essential ingredients in restoring trust include academic oversight of clinical trials, independent statistical analyses, and placing datasets into the public domain."

He added his own personal thoughts. "Physicians involving in leading clinical trials should not participate in marketing activities for sponsors, such as speaker's bureaus," said Dr. Nissen. "I would also take a tougher stand on use of medical writers. In my opinion, writers paid by industry should have no role in preparation of manuscripts reporting clinical trial outcomes."

Keywords: Government, Public Sector, Drug Industry, Marketing, Biomedical Research

< Back to Listings